The current resurgence of whooping cough is alarming and improved pertussis vaccines are 
Introduction
The resurgence of whooping cough in the vaccinated population [1] [2] [3] [4] demands improved pertussis vaccines. Two types of pertussis vaccines are marketed: whole-cell (wPV) and acellular vaccines (aPV). Other types are under development, such as live attenuated and outer membrane vesicle pertussis vaccines (omvPV) [5, 6] . These vaccines differ largely in their composition. The first marketed vaccines were wPVs, which are inactivated bacteria that are naturally adjuvated with bacterial components, such as lipopolysaccharide (LPS) [6] [7] [8] . Despite an acceptable vaccine efficacy, wPVs were found to be reactogenic due to the presence of endotoxins. This lead to the development of alum-adjuvated aPVs containing one to five purified pertussis antigens: pertussis toxoid (Ptd), filamentous hemagglutinin (FHA), pertactin (Prn), and fimbriae types 2 and 3 (Fim2 and Fim3). Despite low reactogenicity of aPVs, waning immunity [9, 10] and persistent transmission of Bordetella pertussis [11] call for reevaluation of aPVs. To retain high vaccine compliance, the target product profile of an improved pertussis vaccine should include better efficacy compared to aPV while maintaining a low reactogenicity.
Currently, antibodies are used as correlates of vaccine-induced immunity for most commercial vaccines [12] , including pertussis vaccines [13, 14] . The protective role of pertussis antibodies was supported by passive immunization studies in naive mice [15, 16] , though cellular responses may also contribute to protection, at least during infection [17, 18] . Antibody responses can be characterized by several parameters, including (i) antigen specificity, (ii) titer, (iii) isotype and subclasses, and (iv) avidity. The IgG antibody subclass profile reflects the T-helper (Th) cell environment [19, 20] . For instance, vaccination with aPV results in the formation of IgG1 antibodies and Th2 cells [21, 22] . Contrarily, vaccination with wPV generates a Th1/Th17 response [23] which is thought to be important for protection against B. pertussis [17, 18, 23] . The functionality of the antibodies is determined by antigen specificity, avidity and antibody subclass. This determines the ability of antiserum to kill bacteria directly or by opsonophagocytic killing through activation of Fc-receptors (FcRs) on phagocytes,
with an important role for FcγRs in the clearance of B. pertussis [24, 25] . For aPV vaccines, antibodies against pertussis toxin (Ptx) and Prn are considered to be protective against a B.
pertussis infection [13, 26, 27] . For wPV, many immunogenic proteins have been identified by 2D-electrophoresis and western blotting [8, 28, 29] . The humoral immune response generated by omvPV is not well defined, although some major antigens were identified [30] and long-lasting immunity observed [31] .
In this study, the systemic humoral response after immunization of mice with an experimental omvPV was compared with the response elicited by classic vaccines, aPV and wPV. Multiplex immunoassays, gel electrophoresis, immunoblotting and mass spectrometry were used to 4 identify the immunogenic antigens and the subclass profiles they induced. Because mice develop sterilizing immunity after a pertussis infection [18] , antisera from B. pertussis-infected mice were included for comparison.
Materials and Methods

Vaccines
B. pertussis B1917 was heat-inactivated (30 min, 56°C) in PBS to produce wPV. Outer membrane vesicles from B. pertussis B1917 (omvPV) were produced as previously described [32] with minor changes. Both wPV and omvPV were diluted in PBS to a final concentration of 4 μg total protein per vaccine dose (300 μl). One human dose of a tetanus-diphtheria-3-component (25 μg pertussis toxoid, 25 μg filamentous hemagglutinin, and 8 μg pertactin) acellular pertussis vaccine (TDaP, Infanrix, GSK) was diluted in PBS (aPV) to a final concentration of 0.25 μg Ptd, 0.25 μg FHA, and 0.08 μg Prn per vaccine dose (300 μl).
Dynamic Light Scattering (DLS)
Particle size was determined by analyzing 0.5 ml of vaccine stock solutions diluted in PBS
(1:100) at 25°C using a Zetasizer Nano-ZS (Malvern Instruments). For each sample, three records of 12 scans were obtained. The Z-average particle size and polydispersity index (PdI)
were calculated using DTS Nano software (Malvern Instruments).
Double stranded (ds) DNA quantitation
Samples were diluted in Tris EDTA (TE) buffer (Invitrogen). Salmon sperm ds-DNA (Invitrogen) was used as standard (0 -2500 ng/ml). In a V-bottom (black) 96-wells plate, 50 µl of each sample or standard was incubated with 50 µl of PicoGreen reagent solution (Invitrogen).
Fluorescence intensity (excitation 480 nm, emission 520 nm) was measured by using a SynergyMx (BioTek Instruments, USA). Concentration of dsDNA was calculated based on the standard curve.
LPS analysis
LPS concentration was determined by analyzing fatty acid composition with a modified gas chromatography method [33] . The peak height of C14:0-3OH was used to quantify LPS, while C12:0-2OH was used as the internal standard. The molecular weight (4057 g/mol [34] ) of B.
pertussis LPS was used to calculate the LPS-concentrations.
Challenge culture
A stock suspension of B. pertussis strain B1917 was diluted with Verweij medium (BBio, Bilthoven, The Netherlands) to a final concentration of 5x10 6 colony-forming units (cfu)/ml.
The cfu concentration was confirmed by plating 100 μL of the bacterial suspension (after 2000-fold dilution in Verweij medium) on Bordet-Gengou agar plates (Cat. no. 254400, BD,
The Netherlands). Plates were incubated for 4 days at 35°C and the number of colonies was counted by using a ProtoCOL colony counter (Synbiosis, Cambridge, United Kingdom). Z Serum Sep GOLD, Greiner Bio-One, Austria). After coagulation (10 min. at room temperature (RT)), sera were collected by centrifugation (10 min., 3000 g) and stored at -80°C for further use.
Animal experiment
Multiplex immunoassay
Serum total IgA, IgG, and IgG subclasses (IgG1, IgG2a, IgG2b and IgG3) levels against pertactin (Prn), filamentous hemagglutinin (FHA), pertussis toxin (Ptx), combined fimbriae type 2 and 3 antigens (Fim2/3), and outer membrane vesicles B1917 (OMV B1917) were determined using a multiplex immunoassay (MIA). Conjugation of OMVs and purified antigens to beads was performed as described previously [35] . Serum was diluted 100-fold or 1250-fold in (GraphPad Software Inc., USA), and presented in fluorescent intensity (F.I.).
Protein digestion by proteinase K treatment
For protein digestion, 5 µg B. pertussis B1917 was incubated (Overnight (ON), 56°C) with 5 µl (20 mg/ml) proteinase K (Proteinase K, recombinant, PCR Grade, Roche). Incubation was terminated by heating the sample for 5 minutes at 100°C.
Sample preparation
Protein concentrations were determined using a bicinchoninic acid (BCA) assay (Pierce). For SDS-PAGE, B. pertussis B1917 (100 µg) was denatured in a total volume of 100 µl 8 M urea (GE Healthcare) in 500 mM bicarbonate (Merck) solution (pH 8.5, 1 h, RT). For 2DE, B. pertussis B1917 (100 µg) was centrifuged (1 min., 16200 g) and the pellet was dissolved and denatured in 100 µl DeStreak Rehydration Solution (GE Healthcare) (1h, RT).
Infrared labeling
IR680 label (15 µg) (Pierce) and IR800 label (100 µg) (Licor) were reconstituted in 100 µl and 25 µl water, respectively. For conjugation of IR800 label to secondary antibodies, 100 µl goatanti-mouse IgG, IgG1, IgG2a, IgG2b, IgG3 or IgA (Southern Biotech) was mixed with 1 µl (4 µg) IR800 label. For IR680 labeling of B. pertussis proteins, 100 µg denatured proteins were mixed with 10 µl IR680 label with optimized concentrations. For 1DE gels and corresponding western blots, a 1:10 and 1:100 dilution of IR-680 stock (0.15 µg/ml) were used, respectively. For 2DE, an undiluted and 1:20 dilution of IR-680 stock (0.15 µg/ml) were used for gels and western blot, respectively. All samples were incubated for 1 hour (RT, in the dark). Subsequently, unbound IR label was removed from samples by using a ZEBA spin desalting column (Pierce) (2 min, 1500 g).
Isoelectric focusing (IEF)
After sample preparation and IR-labeling, samples for 2DE (25 µg B. pertussis proteins) were 
Gel electrophoresis
For SDS-PAGE, 10 µg B. pertussis (B1917) lysate, 1 µg of Prn P.69 (in house prepared [36] ), Ptx (Kaketsuken, Japan), FHA (Kaketsuken, Japan), or Fim2/3 (Sanofi) were incubated (10 min., 100°C) with 3.3 µl reducing sample buffer (250 mM Tris, 8% SDS, 400 mM DTT, 40% Glycerol, 0.04% bromophenol blue) and loaded on a 10% NuPAGE bis tris 1.0-mm precast gel (Invitrogen). For 2DE, the equilibrated strip was placed on a 4-12% NuPAGE Novex bis-tris ZOOM gel (Invitrogen) and sealed with agarose sealing buffer (Bio-rad). Proteins were separated (SDS-PAGE, 45 min., 200 V) (2DE, 50 min., 200 V) with MES running buffer (Invitrogen) in a Xcell surelock minicell electrophoresis system (Invitrogen). Gels were washed in water and either stained with Coomassie (Imperial protein stain, Thermo Scientific), used for western blot or scanned using an Odyssey infrared imager (Westburg).
Western blotting
Nitro-cellulose membrane (Biorad), filters (Biorad) and gel were equilibrated in transfer buffer 
Delta2D analysis
Image warping and spot detection on 2DE gels and western blots were done by using Delta2D software (Version 4.5) (Decodon, Germany). Images of 2DEWB using five distinct sera (omvPV, wPV, aPV, infection and control) were merged by using the Delta2D group warping strategy for IgA, IgG and IgG subclasses individually. Subsequently, spot detection was performed and the intensities were measured in grey values.
In-gel protein digestion for LC-MS/MS analysis
Spots were manually excised from the acrylamide gel. In-gel digestion was performed according to a protocol based on Yan et. al [37] . Briefly, individual gel spots were cut in pieces of about 1 mm3 and washed three times with water, followed by washings with 50% acetonitrile and 100% acetonitrile for dehydration. Trypsin 
Protein digestion for LC-MS/MS analysis
Samples (omvPV or wPV) were diluted in a denaturation buffer containing 1 M guanidine hydrochloride (Gnd-HCl) and 50 mM triethyl ammonium bicarbonate, pH 8. 
Peptide identification by LC-MS/MS analysis
Samples were analyzed by nano-scale reversed-phase liquid chromatography electrospray mass spectrometry, according to the method by Meiring et al. [39] . The analysis was performed on LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Germany).
Analytes were loaded on a trapping column (Reprosil-Pur C18-AQ 5 µm (Dr. Maish, Germany); 
Data handling for total vaccine protein digests
Proteome Discoverer software (version 1.4.1.14, Thermo) was used for peak area determination, identification and relative quantification of the LC-MS/MS raw data. Identification of peptides was performed by searching MS/MS spectra against the protein database of B. pertussis Tohama (NCBI 257313) (3261 entries) and B. pertussis B1917 (3513 entries) [40] using the SEQUEST HT mode. Asparagine deamidation and methionine oxidation were set as variable modifications and lysine dimethylation (light) as a fixed modification. The data were searched with full trypsin cleavage specificity, allowing 2 miscleavages. Precursor ion and MS/MS tolerances were set to 5 ppm and 0.6 Da, respectively. Peptides were filtered to 1% FDR using Perculator (Proteome Discoverer, Thermo). Relative protein concentrations were calculated using the quantification module of Proteome Discoverer using default settings (light: 28.013
Da, heavy 32.055 Da). The molar concentration of proteins was estimated according to
Silva et. al. [41] , except that the peptides were dimethyl-labeled in our method. The molar concentrations were converted to mass concentrations by multiplying with the molecular masses of the proteins. The percentage of protein abundance for each individual protein relative to the total sum of all identified proteins was used to determine an estimated protein amount in one vaccine dose (4 μg total protein) of wPV and omvPV.
Data handling for in-gel protein digests
Proteome Discoverer software was used for identification of the LC-MS/MS raw data for ingel digested proteins almost in a similar way as described in data handling for total vaccine protein digests. Asparagine deamidation and methionine oxidation were set as variable modification. The data were searched with full trypsin cleavage specificity, allowing 2 miscleavages. Precursor ion and MS/MS tolerances were set to 5 ppm and 0.6 Da, respectively.
Peptides were filtered to 1% FDR using Perculator.
Bioinformatics
Functional enrichment with an over-representation analysis (ORA) of the detected B. pertussis proteins was carried out by using DAVID [42] based on Gene Ontology Biological Processes (GO-BP), Molecular Function (GO-MF) and Cellular Component (GO-CC).
Results
Characteristics and composition of pertussis vaccines
The outer membrane vesicle vaccine (omvPV), heat-inactivated whole-cell vaccine (wPV), and acellular vaccine (aPV) were characterized with respect to particle size, DNA content, LPS concentration and protein composition ( Table 1) . OMVs were about ten times smaller in diameter (114 nm) than the inactivated bacteria in the wPV (1156 nm). Further, the omvPV contained a small amount of DNA per vaccine dose (0.2 µg) when compared to wPV (1.2 µg), whereas aPV contained undetectable levels of DNA. In addition, the LPS concentration was slightly lower in omvPV compared to wPV. Additional Adjuvant --Al(OH) 3 1 N/M = Not measured. 2 Based on the vaccine dose of 4 µg total protein for omvPV and wPV. 3 Analysis n = 1 (All other analysis n = 3) LC-MS analysis was performed to characterize total vaccine protein composition of omvPV and wPV. In total, 268 and 332 proteins were identified and quantified in omvPV and wPV, respectively (Table S1 ). Obviously, these numbers do not cover the identification of all proteins present in both vaccines, as B. pertussis has more than 3500 genes. However, this LC-MS method identified and quantified the most abundant proteins present in the vaccines.
The quantity of different proteins differed remarkably between omvPV and wPV. For both vaccine formulations, the top 25 of most abundant proteins is shown in Figure 1A . The 25 proteins that are most abundant in omvPV cover 86% of the total protein content in omvPV.
Autotransporters Vag8 (34%) and BrkA (24%) are the major antigens. The other proteins of the top 25 contributed each less than 5% of the total protein amount. For wPV, the top 25 of proteins of this vaccine covered 67% of the total protein content. GroEL (17%) and FHA (11%)
were the most abundant proteins in wPV. Next, the relative amounts of each individual protein present in omvPV and wPV were compared between both vaccines ( Figure 1B) . In addition, functional analysis using DAVID [42] revealed that nuclear, cytoplasmic and inner membrane proteins were more abundant in wPV, whereas omvPV was enriched for outer membrane proteins and lipoproteins. Periplasmic proteins were present in similar amounts in both vaccines. The protein composition of aPV was not investigated, since it is specified by the manufacturer (one human dose contains 25 µg FHA, 25 µg Ptx and 8 µg Prn).
By using 2-dimensional electrophoresis (2DE), 182 spots were visualized in omvPV and 270 in wPV (Figure 2A and 2B, respectively) . The most intense spots were isolated and the proteins present identified by LC-MS after in-gel protein digestion. The 25 most abundant proteins in omvPV as determined by total vaccine protein LC-MS analysis could also be recovered from the 2DE gels. For wPV, five proteins (bpH1, bpH2, cspA, rplC, BP3037) (see Figure 1) were not found by 2DE, presumably because their isoelectric point (pI) was outside the range (3-10) of the IPG-strip.
Serum levels and subclass distribution of antibodies against antigens in OMVs and aPV.
Serum IgG levels against purified antigens (Prn, Ptx, FHA and Fim2/3) as well as B. pertussis
OMVs were determined in mice vaccinated subcutaneously with omvPV, wPV or aPV at day 0 and day 28. In addition, a group of mice was intranasally infected with B. pertussis at day 0.
Vaccination with omvPV induced the highest concentration of anti-OMV IgG, followed by wPV and intranasal infection, whereas anti-OMV IgG was absent after aPV vaccination (Figure 3A 
.). (A)
The antibody levels were determined in 1:100 diluted sera. (B) Samples exceeding the detection limit were further analyzed by using a 1:1250 serum dilution. In addition, the antibody concentrations of IgG-subclasses (C) IgG1, (D) IgG2a, (E) IgG2b and (F) IgG3, as well as (G) IgA antibodies were determined in 1:100 diluted serum samples. No pertussis-specific antibodies were measured in serum of naive mice (Figure 3A-G) .
Heterogeneity of antigen specificity and anti-LPS antibodies identified by using immunoblotting
A combination of 1-dimensional gel electrophoresis and western blotting (1DEWB) was used in order to identify the antigen-specificity of the antibody isotypes or subclasses elicited by the different vaccines (Figure 4) . 1DEWB unraveled staining against 22 bands in a B. pertussis lysate, as marked in lane 21 and 35 ( Figure 4A) . The most intense staining was obtained with sera from omvPV-vaccinated mice. In addition, it was observed that antibody subclass formation is antigen specific in some cases. For instance, antibodies against band 16 were only formed upon omvPV vaccination and were exclusively of the IgG2a subclass. A broad subclass induction was observed in these sera for the other antigens ( Figure 4A, lane 3-8 
Discussion
This study demonstrates that vaccination with three different pertussis vaccines (omvPV, wPV or aPV) elicited distinct differences in humoral responses, not only with respect to antigenspecificity and antibody levels, but also with respect to antibody isotypes and IgG subclasses. pertussis B1917 proteome were identified by 2-dimensional immunoblotting and subsequent LC-MS analysis.
To our best knowledge, this is the first time that immunoproteomic profiles of different pertussis vaccines were extensively compared. This study will be useful for understanding host-pathogen interaction and for vaccine design, since complete subclass profiling, especially regarding IgG2b and IgG3, is often absent [15, 43] . Distinct variances in IgG subclass response [19, 20, 44] . In mice, Th1 type responses promote the production of IgG2a, whereas Th2 responses stimulate the formation of IgG1 [19, 44] . In addition, production of IgG2b seems to be linked to a Th17 type response [20] . Whereas all types of T-cell help stimulate the secretion of IgG3 [19, 44] , the highest IgG3 formation is achieved by T-cell independent antibody responses by B-cells, i.e. against LPS [45] .
The differences in IgG subclass responses observed in the mice upon vaccination with different pertussis vaccines are likely influenced by the vaccine characteristics, such as (i) particle size, (ii) vaccine composition or (iii) presence of adjuvants, along with (iv) the route of administration. For instance, OMVs are ten times smaller in diameter than whole bacteria.
This may increase the exposure to different cell types because there are more particles present in the omvPV or affect the uptake by different cell types with respect to efficiency in uptake and routing within the cells [46] . In addition, OMVs may reach immune cells deeper in the tissue, which are less accessible for the whole bacteria or the large alum particles [47] , or drain faster (unprocessed) to the lymph nodes [46] , thereby affecting the immune responses induced.
Further, the presence of natural immune potentiators or co-administered adjuvants is known to influence the type of immune response. No adjuvants were added to the omvPV and wPV vaccines. However, these vaccine formulations do contain LPS and bacterial DNA, which are agonists for TLR4 and TLR9, respectively [48] . Activation of these pathogen recognition receptors stimulates and directs the humoral immune response in a T-cell dependent or independent way [49] . The higher concentrations of LPS and especially DNA detected in wPV, when compared to omvPV, might partly explain the different subclass responses. In addition, LPS-recognition by TLR4 in synergy with the B-cell receptor may also lead to direct T-cell independent anti-LPS antibody formation, especially IgG3, by B-cells [45] . In the case of aPV, the presence of aluminum hydroxide leads to a Th2 biased response [50] and subsequently the formation of IgG1 against purified pertussis antigens [22] , as was also found in this study.
Interestingly, it was shown that this Th2 response caused by aluminum-containing vaccines could be steered towards a Th1 response by addition of TLR ligands that induce strong Th1 responses, such as an LPS derivate (TLR4 ligand) [51] or CpG (TLR9-agonist) [52] . This indicates that the sum of all interactions within and between activated pathways determines the environmental conditions in which the B-cells reside, and consequently the outcome of the humoral response.
The intranasal infection resulted in production of IgG2a and IgG2b, which is thought to be related to a Th1/Th17 response [18, 20] . An enhanced IgG2a antibody formation, relative to IgG1, was also found upon intranasal administration of live attenuated pertussis vaccine [5] .
A bacterial infection results in colonization and protein secretion of the bacteria leading to prolonged antigen exposure [18] when compared to vaccination. The intranasal route of administration of the infection, compared to subcutaneous vaccination with omvPV, wPV or aPV, at least partly explains the exclusive presence of serum IgA antibodies in infected mice [18] .
Antibody subclasses determine the functionality of antibodies, since IgG subclasses may have a different bactericidal and opsonophagocytic activity [53] . Recently, it was suggested that for B. pertussis, antibodies with opsonophagocytic killing functionality might be more important compared to direct serum bactericidal killing [54] . For B. pertussis, Fc-receptors play an important role in opsonophagocytic killing in the respiratory tract in mice [24, 25] .
IgG subclasses have a different affinity and selectivity towards FcRs [55] . In mice, IgG1 predominantly targets FcγRIII (CD16) [56] . FcγRIV (CD16-2) exclusively binds IgG2a and IgG2b that both have the highest affinity for this receptor but are able to bind all FcRs [57] . Finally, murine IgG3 has a high affinity for FcRn and low affinity for FcγRI (CD64). Fc-receptors are present on several cell types such as B-cells and NK-cells, but predominantly on phagocytes, such as neutrophils and macrophages [55] . The neutrophils seem essential to protect against B. pertussis, since neutrophil depletion resulted in impaired lung clearance, especially in immunized mice [58] . The present study showed the essence of characterization of complex vaccines for understanding antibody profiles. In another study describing the antigenic composition of an omvPV, Ptx and Fim2 were reported to be present in that vaccine [30] . However, this was not observed in our study using a different omvPV. The differences in vaccine composition might be explained by the use of different B. pertussis strains, culture conditions, OMV extraction methods [38] , vaccine dose, and methods of analysis. Though some antigens that were most abundant induced the highest antibody responses (such as Vag8 and BrkA in omvPV), other abundant proteins (such as FHA and Prn in omvPV and wPV) did not induce that high antibody responses, whereas some less abundant proteins (Pnp, BvgA) induced higher responses than expected based on the quantity present. In addition, some proteins present in equal amounts in omvPV and wPV (Tcf, EfTu) induced different antibody levels.
While many immunogenic proteins are present in omvPV and wPV, little is known about their protective capacity. Some indications have been reported, for example, using a mouse intracerebral protection assay it was shown that in combination with non-protective levels of anti-Ptx, Vag8 induced protective activity [60] . In addition, when administered as a single component vaccine, recombinant Vag8 could induce a protective response in the lung [16] .
For another autotransporter, BrkA, human antibodies against this protein were shown to have bactericidal activity [61] . In addition, a three-component acellular vaccine with BrkA, Ptx and FHA was shown to induce a protective immune response in mice [62] . However, vaccination with recombinant BrkA as a single component did not protect against B. pertussis infection [62] . The tracheal colonization factor (Tcf) is a virulence factor and aerosol challenge of mice with a Tcf-deficient B. pertussis strain resulted in a 10-fold decrease in trachea colonization compared to a WT strain, indicating an important role for Tcf during colonization [63] . This might suggest a protective function for anti-Tcf antibodies in the respiratory tract.
Indeed, intranasal administration of Tcf, carried by an attenuated strain of Vibrio cholerae, resulted in clearance of B. pertussis in the trachea, but not in the lungs of vaccinated mice [64] . The GroEL protein is a conserved protein, found in many species of bacteria as well as in humans and therefore probably less suitable as a vaccine antigen [65] . In this study, anti-GroEL antibody formation was found upon wPV vaccination and B. pertussis infection.
Active immunization with GroEL induced only little protection against a B. pertussis infection [65] . In the present study, anti-LPS antibodies were detected at high levels in mice vaccinated with omvPV or wPV and to a lesser extent in infected mice. Others have demonstrated that anti-LPS antibodies in mice [66] , rats [67] , and humans [68] have bactericidal activity and reduce bacterial colonization in the respiratory tract. In addition, anti-LPS antibodies might lead to diminished pro-inflammatory cytokine production by binding LPS, leading to reduced endotoxic effects of an infection. Immunization with LPS-based oligosaccharide conjugates induced bactericidal antibodies, indicating the potential for improving immunity by implementing pertussis LPS in a vaccine [69] .
The question remains whether omvPV provides protective immunity by eliciting a humoral immune response. Based on the protective capacity of antibody induction against antigens, such as BrkA, LPS, Tcf and Vag8 described in literature [61, 64, 69, 70] , the omvPV antibody profile in our study suggests potential induction of protective humoral immunity in mice.
Other studies have shown that omvPV confers protection similar to aPV when studying the short-term responses [6, 31] . More importantly, it was shown that omvPV could also provide long-lasting immunity. This was also achieved by a commercial aPV but only at a high dose (1/10 Human Dose) in mice [31] . In addition, omvPV protects against different strains [31] .
The broader response against multiple relevant antigens by omvPV, instead of selective antigens by aPV, may prevent impaired immunity due to strain adaptation. Future studies should demonstrate the relationship between the immunoproteomic profiles determined for different pertussis vaccines and the presence of long lasting-immunity. These studies should provide us with important new insights into the role of the humoral response and protection.
In order to maintain high vaccine compliance after introducing an improved pertussis vaccine, first a better efficacy but not more reactogenicity of omvPV compared to aPV should be established.
In conclusion, the humoral immune response elicited by omvPV is distinct from that induced by classic pertussis vaccines, such as wPV and aPV. The omvPV elicits high serum antibody levels that consist of a broad subclass response in mice against multiple antigens. The study supports wider exploration of omvPV as an improved pertussis vaccine.
